Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab
- Additional Document Info
- View All
Eczema and eczematous reactions induced by interleukin (IL)-17 inhibitors in patients with psoriasis are established adverse events (1), which may be reported as adverse events (AEs) in up to 12.1% patients on anti-IL-17 treatment in controlled clinical trials (2-5). We performed an integrated safety analysis of 13 clinical studies to evaluate the frequency and management of the treatment-emergent adverse events (TE-AEs) of eczema and clinical variants in patients with moderate-to-severe psoriasis treated with ixekizumab (IXE), a selective inhibitor of IL-17A, to better understand the nature of these events.
has subject area